Welcome to our dedicated page for Gossamer Bio news (Ticker: $GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gossamer Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gossamer Bio's position in the market.
Gossamer Bio, Inc. (NASDAQ: GOSS) granted non-executive employees stock options under the 2023 Inducement Plan. The options allow the purchase of up to 323,000 shares at $0.755 per share, vesting over four years. This grant aims to incentivize and retain new employees in accordance with Nasdaq rules.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced its first quarter 2024 financial results and business update. The company reported $396 million in cash, pro forma for a $160 million reimbursement payment and debt repayment. They are collaborating with Chiesi for seralutinib development and co-commercialization. The PROSERA Phase 3 study for PAH is ongoing, with top-line results expected in Q4 2025. A registrational Phase 3 study for PH-ILD is set to begin in mid-2025. TORREY Phase 2 PAH results were published in Lancet Respiratory Medicine, with additional data to be presented at ATS in May.
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize Seralutinib for pulmonary hypertension. Gossamer will receive development reimbursement and milestones payments, leading the US commercialization activities. Chiesi obtains exclusive ex-US commercial rights with Gossamer receiving royalties on net sales. A Phase 3 trial of Seralutinib in PH-ILD is planned for mid-2025.
Gossamer Bio, Inc. announced the publication of the TORREY Phase 2 study results in the Lancet Respiratory Medicine, showcasing the positive impact of seralutinib in treating pulmonary arterial hypertension. The study demonstrated significant improvements in pulmonary vascular resistance and other key disease measures. This milestone sets the stage for the Phase 3 PROSERA Study, highlighting the potential of seralutinib to enhance the quality of life for PAH patients.